15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The PlagL2 transcription factor activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cytokine signaling pathways are frequent targets of oncogenic mutations in acute myeloid leukemia, promoting proliferation and survival. We have previously shown that the transcription factor PLAGL2 promotes proliferation and cooperates with the leukemia fusion protein Cbfβ-SMMHC in acute myeloid leukemia development. Here we show that PLAGL2 upregulates expression of the thrombopoietin receptor Mpl, using 2 consensus sites in its proximal promoter. We also show that Mpl overexpression efficiently cooperates with Cbfβ-SMMHC in development of leukemia in mice. Finally, we demonstrate that PlagL2-expressing leukemic cells show hyper-activation of Jak2 and downstream STAT5, Akt and Erk1/2 pathways in response to Tpo ligand. These results show that PlagL2 expression activates expression of Mpl in hematopoietic progenitors, and that upregulation of wild type Mpl provides an oncogenic signal in cooperation with CBFβ-SMMHC in mice.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Prognostically useful gene-expression profiles in acute myeloid leukemia.

          In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis. Copyright 2004 Massachusetts Medical Society
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inducible gene targeting in mice.

            A method of gene targeting that allows the inducible inactivation of a target gene in mice is presented. The method uses an interferon-responsive promoter to control the expression of Cre recombinase. Here, Cre was used to delete a segment of the DNA polymerase beta gene flanked by IoxP recombinase recognition sites. Deletion was complete in liver and nearly complete in lymphocytes within a few days, whereas partial deletion was obtained in other tissues. This method can be used for the inducible inactivation of any other gene in vivo.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Oncogenic transcription factors in the human acute leukemias.

              Chromosomal translocations in the human acute leukemias rearrange the regulatory and coding regions of a variety of transcription factor genes. The resultant protein products can interfere with regulatory cascades that control the growth, differentiation, and survival of normal blood cell precursors. Support for this interpretation comes from the results of gene manipulation studies in mice, as well as the sequence homology of oncogenic transcription factors with proteins known to regulate embryonic development in primitive organisms, including the nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster. Many of these genetic alterations have important prognostic implications that can guide the selection of therapy. The insights gained from studies of translocation-generated oncogenes and their protein products should hasten the development of highly specific, and hence less toxic, forms of leukemia therapy.
                Bookmark

                Author and article information

                Journal
                8704895
                5536
                Leukemia
                Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K
                0887-6924
                1476-5551
                8 November 2010
                25 January 2011
                April 2011
                1 October 2011
                : 25
                : 4
                : 655-662
                Affiliations
                [1 ] Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester MA 01605.
                [4 ] Departments of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester MA 01605.
                Author notes
                [5 ]Correspondence to: Lucio H Castilla, Ph.D., Program in Gene Function and Expression, University of Massachusetts Medical School, 364 Plantation Street, Worcester MA 01605. Tel.: (508) 856-3281, Fax: (508) 856-5460, Lucio.Castilla@ 123456Umassmed.edu
                [2]

                Equal contribution to this work.

                [3]

                Current address: Yale School of Medicine, 295 Congress Avenue, New Haven CT 06519

                Article
                nihpa245943
                10.1038/leu.2010.301
                3076538
                21263445
                e4132560-680e-4a70-aa08-60bcf7dcc7a3

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Cancer Institute : NCI
                Award ID: R01 CA096983-08 ||CA
                Categories
                Article

                Oncology & Radiotherapy
                transcription factors,mpl,gene regulation,plagl2,acute myeloid leukemia,cbfb-myh11

                Comments

                Comment on this article